Lumida
/STAA
⌘K
STAAR Surgical Co

STAAR Surgical Co

STAA
$22.66USD-3.25%-0.76 today

MARKET CAP

1.1B

P/E (TTM)

FWD P/E

DAY RANGE

$22 – $24

52W RANGE

$16
$36

AI Summary

Stalk
TrimMedium

STAA is in a sustained medium- and long-term downtrend under a Stage 4 decline. A decisive Support Failure breakdown confirms continued supply dominance. Price is extended below major EMAs in extreme oversold territory, leaving short-term timing unclear. Execution should be deferred, awaiting a failed relief rally into the EMA zone before engaging further.

  • Q1 net sales $93.5M (+119.6% YoY) driven by China and Americas
  • Q1 adjusted EBITDA $24.4M, swinging from a $26.4M loss last year
  • China Q1 sales collapsed to $389K from $38.5M YoY, highlighting market risk
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2026TREND
Sales, Adj.$230.5M$284.4M$322.4M$313.9M$239.4M
YoY %+41.0%+23.4%+13.4%-2.6%-23.7%
P / Sales19.6x8.4x4.8x3.8x4.9x
EV / Sales19.1x8.4x4.5x3.7x4.7x
Gross Profit, Adj.$178.6M$223.4M$252.7M$239.6M$182.4M
YoY %+50.9%+25.0%+13.1%-5.2%-23.9%
Margin %77.5%78.5%78.4%76.3%76.2%
EV / Gross Profit24.6x10.7x5.8x4.8x6.2x
EBITDA, Adj.$37.0M$48.3M$33.2M$-5.7M$-54.4M
YoY %+274.9%+30.6%-31.2%-117.2%-850.2%
Margin %16.0%17.0%10.3%-1.8%-22.7%
EV / EBITDA119.1x49.5x44.0x-202.3x-20.7x
EBIT$33.3M$43.8M$28.1M$-12.6M$-91.7M
YoY %+392.5%+31.4%-35.9%-144.9%-627.2%
Margin %14.5%15.4%8.7%-4.0%-38.3%
EV / EBIT132.1x54.6x52.0x-91.8x-12.3x
Net Income$27.5M$39.7M$21.3M$-20.2M$-80.4M
YoY %+365.3%+44.2%-46.2%-194.7%-298.1%
Net Margin11.9%13.9%6.6%-6.4%-33.6%
EPS (GAAP)$0.56$0.80$0.43-$0.41-$1.62
YoY %+366.7%+42.9%-46.3%-195.3%-295.1%